首页 | 本学科首页   官方微博 | 高级检索  
检索        

胰腺癌高表达抗原MUC4 CTL表位肽的体内免疫原性
引用本文:范柳笛,张岩,时冉冉.胰腺癌高表达抗原MUC4 CTL表位肽的体内免疫原性[J].中国病理生理杂志,2018,34(3):441-446.
作者姓名:范柳笛  张岩  时冉冉
作者单位:漯河医学高等专科学校医学生物工程重点实验室, 河南 漯河 462002
基金项目:河南省高等学校重点科研项目(No.18B180019)
摘    要:目的:检测来源于黏蛋白4(MUC4)的人白细胞抗原(HLA)-A2限制性表位肽免疫BALB/c小鼠后产生细胞免疫应答的水平,筛选出体内具有免疫原性的HLA-A2限制性表位肽。方法:将来源于MUC4的候选HLA-A2限制性表位肽、通用性Th表位和弗氏不完全佐剂联合应用皮下免疫BALB/c小鼠,用酶联免疫斑点实验(ELISPOT)和酶联免疫吸附实验(ELISA)检测小鼠脾细胞表位肽特异性细胞免疫应答的水平,体内细胞毒实验活性检测候选肽诱导细胞毒性T淋巴细胞(cytotoxic lymphocyte,CTL)的能力,并用流式细胞术检测表位肽特异性的CD8+T细胞所占比例。结果:在检测的4个表位肽中,P2004-1Y9V诱导BALB/c小鼠产生的细胞免疫应答最强,细胞毒实验结果显示,P2004和P2004-1Y9V对CAPAN-2细胞均有一定的杀伤作用,且P2004-1Y9V特异性CTLs对CAPAN-2细胞杀伤率高于原肽(P0.05)。胞内因子染色实验进一步表明P2004-1Y9V免疫后可产生特异性的CD8~+T细胞。结论:在来源于MUC4的HLA-A2限制性表位肽中,P2004-1Y9V具有较强的体内免疫原性,可以作为潜在的肿瘤多肽疫苗应用于临床研究。

关 键 词:黏蛋白4  表位  体内免疫原性  HLA-A2限制性表位肽  
收稿时间:2017-09-07

In vivo immunogenic characteristics of cytotoxic T lymphocyte epitopes from pancreatic tumor antigen MUC4
FAN Liu-di,ZHANG Yan,SHI Ran-ran.In vivo immunogenic characteristics of cytotoxic T lymphocyte epitopes from pancreatic tumor antigen MUC4[J].Chinese Journal of Pathophysiology,2018,34(3):441-446.
Authors:FAN Liu-di  ZHANG Yan  SHI Ran-ran
Institution:Key Laboratory of Medical Bioengineering, Luohe Medical College, Luohe 462002, China
Abstract:AIM: Peptide vaccines have been conceived as promising therapies for tumor-inflicted patients due to their easy production and capability of inducing specific immune response required for defending the tumor. During our previous research, 4 HLA-A2-restricted peptides had been identified as immunogenic in vivo. In this study, we aimed to testify the in vivo immunogenicity of the 4 peptides. METHODS: BALB/c mice were vaccinated with HLA-A2 restricted peptides emulsified in incomplete Freund's adjuvant (IFA) subcutaneously in combination with the epitope at the adjacent location. After the 3rd peptide vaccination for 10 d, the peptide-specific immune response was evaluated by ELISPOT and ELISA. The ability to induce T cell response was investigated by using cytotoxicity assay in vivo and the presence of peptide-specific CD8+ T cells capable of recognizing the MHC-peptide was detected by flow cytometry. RESULTS: Among the 4 candidate HLA-A2 restricted peptides, the immune response elicited by P2004-1Y9V was superior to that of the other 3 peptides. The CTLs induced by P2004 and P2004-1Y9V lysed CAPAN-2 cells. P2004-1Y9V peptide-specific CTLs showed higher cytotoxicity against pancreatic tumor cell lines of CAPAN-2 than the native peptide-specific CTLs. Intracellular cytokine staining assay indicated the presence of P2004-1Y9V specific CD8+T cells in the P2004-1Y9V vaccinated mice. CONCLUSION: P2004-1Y9V is the most immunogenic peptide in vivo, and can be explored as potential tumor peptide vaccine in the future clinical study.
Keywords:Mucin 4  Epitopes  In vivo immunogenicity  HLA-A2-restricted peptides
本文献已被 CNKI 等数据库收录!
点击此处可从《中国病理生理杂志》浏览原始摘要信息
点击此处可从《中国病理生理杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号